Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive/HER2-positive breast cancer - The TOUCH trial

被引：0
|
作者：
Biganzoli, Laura
Brain, Etienne
Malorni, Luca
Gombos, Andrea
Hasler-Strub, Ursula
Zamagni, Claudio
Chakiba, Camille
Roschitzki-Voser, Heidi
Regan, Meredith M.
机构：
[1] Int Breast Canc Study Grp, Bern, Switzerland
[2] TOUCH Investigators, Bern, Switzerland
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT-28-02
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Patel, Tejal A.
    Ensor, Joe E.
    Creamer, Sarah L.
    Boone, Toniva
    Rodriguez, Angel A.
    Niravath, Poly A.
    Darcourt, Jorge G.
    Meisel, Jane L.
    Li, Xiaoxian
    Zhao, Jing
    Kuhn, John G.
    Rosato, Roberto R.
    Qian, Wei
    Belcheva, Anna
    Schwartz, Mary R.
    Kaklamani, Virginia G.
    Chang, Jenny C.
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [12] Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN)
    Rimawi, Mothaffar F.
    Poole, Christopher John
    Ferrero, Jean-Marc
    Rodriguez, Juan R. De la Haba
    Mitchell, Lada
    Pelizon, Christina H.
    Arpino, Grazia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [13] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Tejal A. Patel
    Joe E. Ensor
    Sarah L. Creamer
    Toniva Boone
    Angel A. Rodriguez
    Poly A. Niravath
    Jorge G. Darcourt
    Jane L. Meisel
    Xiaoxian Li
    Jing Zhao
    John G. Kuhn
    Roberto R. Rosato
    Wei Qian
    Anna Belcheva
    Mary R. Schwartz
    Virginia G. Kaklamani
    Jenny C. Chang
    Breast Cancer Research, 21
  • [14] A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
    Waks, Adrienne G.
    Desai, Neelam V.
    Li, Tianyu
    Poorvu, Philip D.
    Partridge, Ann H.
    Sinclair, Natalie
    Spring, Laura M.
    Faggen, Meredith
    Constantine, Michael
    Metzger, Otto
    Alberti, Jillian
    Deane, Julia
    Rosenberg, Shoshana M.
    Frank, Elizabeth
    Tolaney, Sara M.
    Krop, Ian E.
    Tung, Nadine M.
    Tayob, Nabihah
    King, Tari A.
    Mittendorf, Elizabeth A.
    Winer, Eric P.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [15] A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
    Adrienne G. Waks
    Neelam V. Desai
    Tianyu Li
    Philip D. Poorvu
    Ann H. Partridge
    Natalie Sinclair
    Laura M. Spring
    Meredith Faggen
    Michael Constantine
    Otto Metzger
    Jillian Alberti
    Julia Deane
    Shoshana M. Rosenberg
    Elizabeth Frank
    Sara M. Tolaney
    Ian E. Krop
    Nadine M. Tung
    Nabihah Tayob
    Tari A. King
    Elizabeth A. Mittendorf
    Eric P. Winer
    npj Breast Cancer, 8
  • [16] Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer
    Hyams, D. M.
    Leichman, G. C.
    Klein, P.
    Rietchsel, P.
    Levine, E. G.
    Gebski, V. J.
    Kelley, M. A.
    CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
  • [17] Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
    Baselga, Jose
    Semiglazov, Vladimir
    van Dam, Peter
    Manikhas, Alexey
    Bellet, Meritxell
    Mayordomo, Jose
    Campone, Mario
    Kubista, Ernst
    Greil, Richard
    Bianchi, Giulia
    Steinseifer, Jutta
    Molloy, Betty
    Tokaji, Erika
    Gardner, Humphrey
    Phillips, Penny
    Stumm, Michael
    Lane, Heidi A.
    Dixon, J. Michael
    Jonat, Walter
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2630 - 2637
  • [18] Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer
    Zhao, Shen
    Liu, Xi-Yu
    Jin, Xi
    Ma, Ding
    Xiao, Yi
    Shao, Zhi-Ming
    Jiang, Yi-Zhou
    THERANOSTICS, 2019, 9 (17): : 4935 - 4945
  • [19] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer
    不详
    GYNAKOLOGE, 2016, 49 (08): : 558 - 558
  • [20] Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial
    Zhong, Xiaorong
    He, Ping
    Chen, Jie
    Yan, Xi
    Wei, Bin
    Zhang, Zhang
    Bu, Hong
    Li, Jing
    Tian, Tinglun
    Lv, Qing
    Wang, Xiaodong
    Li, Hongjiang
    Wang, Jing
    Huang, Juan
    Suo, Jiaojiao
    Liu, Xiaoxiao
    Zheng, Hong
    Luo, Ting
    GLAND SURGERY, 2022, 11 (01) : 216 - +
12345